ESTRO 36 Abstract Book

536 / 1082

S521 ESTRO 36 2017
_______________________________________________________________________________________________
concurrent Cisplatin and 5-Flurouracil followed by,
10Gy/2Fr of ILBT boost once weekly. The patients with
local advanced disease for palliation received 36Gy/12Fr
through EBRT followed by, 10Gy/2Fr of ILBT once weekly.
The outcome of treatment was assessed in terms of
dysphagia score, dysphagia free survival, toxicities and
overall survival.
Results
Median age of patients was 55 years. Histopathologically
96 % has Squamous cell carcinoma. 16 (64%) of patients
were treated with definitive radiotherapy while the rest,
9 (36%) with palliative intent. At a median follow up of 9
months, 13 patients were dysphagia free and there were
5 deaths. One month after completion of treatment, 18
patients were dysphagia free while, 2 patients had partial
relief and 5 patients did not notice any relief in dysphagia.
2 patients died within 6 months of completion while, 2
patients developed trachea-esophageal fistula during
follow-up.
Conclusion
ILBT is a safe modality for boost in treatment of carcinoma
esophagus provided, the patients are sele cted with
caution.
PO-0949 Evaluation of role of Interstitial
Brachytherapy in Soft Tissue Sarcoma: Single institute
experience
V. Pareek1
1 Jupiter Hospital- Thane, Radiation Oncology, Mumbai,
India
Purpose or Objective
Soft tissue Sarcomas are rare group of solid tumors
comprising of 1% of all solid tumors. The management of
soft tissue sarcomas have evolved due to advancements in
imaging, histopathology, cytogenetics, and the use of
multimodality treatment. The treatment strategies
emphasizes on the control of disease locally, sparing of
limb function and improvement in the quality of life. High
dose brachytherapy has formed a part of the management
and has the advantage of providing concentrated dose to
tumors and sparing of surrounding normal tissues. In this
study we examined the clinical outcome of High dose
Brachytherapy for STS at our Hospital through
retrospective analysis of the prospective database
maintained.
Objectives: To review the clinical outcome and quality of
life in patients with Soft Tissue Sarcoma treated at our
center through High dose rate interstitial brachytherapy.
Material and Methods
Twenty patients with different sites and grades of Soft
Tissue Sarcoma underwent surgery and Intraoperative
catheter implantations in single plane in biopsy proven
Soft tissue sarcoma cases. These patients then underwent
High Dose Brachytherapy with Iridium – 192. The patients
received average dose of 3.5Gy per Fraction (Two
fractions per day 6 hours apart) with total dose of 35
Gy/10 Fr/5 Days and after completion of treatment were
followed up at 1 month and later every 3 monthly for 2
years; Followed by 6 monthly interval.
Results
The Patients were followed up for range of 6 – 42 months
(Median 25 months) and overall control rate was 72.72%.
The Local recurrence was noted in only one patient
(9.09%) and two patients developed distant metastases
(18.18%). The dosimetric outcomes were assessed and
results analyzed related to the dose to the surrounding
organs at risk. The quality of life parameters were also
assessed prior to treatment and later during follow ups
and results showed better quality of life parameters.
Conclusion
The results in our study suggested the importance of HDR
Brachytherapy in management of Soft Tissue Sarcoma. The
local control rate was 72.72 %. The dose of 35Gy over 10
fractions over 5 Days was found to be effective in local
control and limb salvage in case of Soft Tissue Sarcoma as
practiced at our Centre.
PO-0950 High-dose-rate brachytherapy treatment in
T1-T2 stage non-melanoma skin cancer patients.
M.A. González Ruiz1, J. Quirós Rivero1, M.F. Ropero
Carmona1, A. Ruiz Herrero1, M.C. Cruz Muñoz1, P. Simón
Silva1, J.J. Cabrera Rodríguez1, J.L. Muñoz García1, Y. Ríos
Kavadoy1, F. García Urra1, P. Almendras Manzano2
1Infanta Cristina Hospital, Radiation Oncology, Badajoz,
Spain
2Infanta Cristina Hospital, Radiophysics, Badajoz, Spain
Purpose or Objective
To analyze the results in terms of overall survival (OS),
cancer specific survival (CSS), local control (LC), cosmesis
and toxicity in patients (pts) with non-melanoma skin
cancer (NMSC) treated with high-dose-rate brachytherapy
(HDR-BT) treatment, plesiotherapy modality; with radical
or adjuvant intention in our hospital.
Material and Methods
Retrospective study of 50 pts with 63 NMSC lesions, T1
(74%) and T2 (26%) stage treated from May 2015 to May
2016. HDR-BT treatment (6 Gy/fraction; total dose 42 Gy)
was used in 48 pts with an equivalent 2 Gy dose (EQD2) of
56 Gy. Median total dose of HDR-BT was 42.6 Gy (range
36-50). All the lesions for the selected cases were limited
3-4 mm depth. Treatment intention was radical in 86% pts
and adjuvant in 14% pts. The median age of the pts was 76
years-old (range 52-94); 64% males. Basal-cell carcinoma
(84%) and face (92,4%) were the most frequent histological
type and location respectively. The 34% of the lesions
were treated with Valencia applicators and 66% with
custom-made moulds. Kaplan-Meier curves have been
used for the statistical analysis of survival. Treatment-
related toxicity was assessed using RTOG and the NCI-
Common Terminology Criteria for Adverse Events
guidelines.
Results
The median follow-up was 18 months (range 7-45). The OS,
CSS and LC was 96%, 100% and 96% respectively. The
majority of pts had acute skin toxicity grade 1-2.
Conjunctival toxicity appeared in 10 % of the pts. Cosmetic
results were considered as excellent/good in all patients.
Conclusion
In patients with NMSC T1 and T2 stage HDR-BT treatment,
plesiotherapy modality is a good alternative treatment for
non-surgical patients. Plesiotherapy treatment provides
excellent results for local control and cosmesis which is a
safe and attractive treatment option.